Stereotactic body radiation therapy (SBRT) for unresectable pancreatic carcinoma

Michael C. Stauder, Robert C. Miller

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Survival in patients with unresectable pancreatic carcinoma is poor. Studies by Mayo Clinic and the Gastrointestinal Tumor Study Group (GITSG) have established combined modality treatment with chemotherapy and radiation as the standard of care. Use of gemcitabine-based chemotherapy alone has also been shown to provide a benefit, but 5-year overall survival still remains less than 5%. Conventional radiotherapy is traditionally delivered over a six week period and high toxicity is seen with the concomitant use of chemotherapy. In contrast, SBRT can be delivered in 3-5 days and, when used as a component of combined modality therapy with gemcitabine, disruption to the timely delivery of chemotherapy is minimal. Early single-institution reports of SBRT for unresectable pancreatic carcinoma demonstrate excellent local control with acceptable toxicity. Use of SBRT in unresectable pancreatic carcinoma warrants further investigation in order to improve the survival of patients with historically poor outcomes.

Original languageEnglish (US)
Pages (from-to)1565-1575
Number of pages11
Issue number3
StatePublished - Sep 2010


  • Pancreatic neoplasms
  • Radiotherapy
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Stereotactic body radiation therapy (SBRT) for unresectable pancreatic carcinoma'. Together they form a unique fingerprint.

Cite this